Display options
Cite
Llerena S, García-Díaz N, Curiel-Olmo S, et al. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget. 2018;9(56):30869-30882doi: 10.18632/oncotarget.25766.
Llerena, S., García-Díaz, N., Curiel-Olmo, S., Agraz-Doblas, A., García-Blanco, A., Pisonero, H., Varela, M., Santibáñez, M., Almaraz, C., Cereceda, L., Martínez, N., Arias-Loste, M. T., Puente, �. �., Martín-Ramos, L., de Lope, C. R., Castillo-Suescun, F., Cagigas-Fernandez, C., Isidro, P., Lopez-López, C., Lopez-Hoyos, M., Llorca, J., Agüero, J., Crespo-Facorro, B., Varela, I., Piris, M. �. �., Crespo, J., & Vaqué, J. P. (2018). Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget, 9(56), 30869-30882. https://doi.org/10.18632/oncotarget.25766
Llerena, Susana, et al. "Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR." Oncotarget vol. 9,56 (2018): 30869-30882. doi: https://doi.org/10.18632/oncotarget.25766
Llerena S, García-Díaz N, Curiel-Olmo S, Agraz-Doblas A, García-Blanco A, Pisonero H, Varela M, Santibáñez M, Almaraz C, Cereceda L, Martínez N, Arias-Loste MT, Puente Á, Martín-Ramos L, de Lope CR, Castillo-Suescun F, Cagigas-Fernandez C, Isidro P, Lopez-López C, Lopez-Hoyos M, Llorca J, Agüero J, Crespo-Facorro B, Varela I, Piris MÁ, Crespo J, Vaqué JP. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget. 2018 Jul 20;9(56):30869-30882. doi: 10.18632/oncotarget.25766. eCollection 2018 Jul 20. PMID: 30112114; PMCID: PMC6089396.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Jul 20;9(56):30869-30882. doi: 10.18632/oncotarget.25766. eCollection 2018 Jul 20.

Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR.

Oncotarget

Susana Llerena, Nuria García-Díaz, Soraya Curiel-Olmo, Antonio Agraz-Doblas, Agustín García-Blanco, Helena Pisonero, María Varela, Miguel Santibáñez, Carmen Almaraz, Laura Cereceda, Nerea Martínez, María Teresa Arias-Loste, Ángela Puente, Luis Martín-Ramos, Carlos Rodríguez de Lope, Federico Castillo-Suescun, Carmen Cagigas-Fernandez, Pablo Isidro, Carlos Lopez-López, Marcos Lopez-Hoyos, Javier Llorca, Jesús Agüero, Benedicto Crespo-Facorro, Ignacio Varela, Miguel Ángel Piris, Javier Crespo, José Pedro Vaqué

Affiliations

  1. Gastroenterology and Hepatology Unit, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  2. Infection, Immunity and Digestive Pathology Group, IDIVAL, Santander, Spain.
  3. Translational Hematopathology Group, IDIVAL, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
  4. Departamento de Biología Molecular, Universidad de Cantabria (UC-IBBTEC), Santander, Spain.
  5. Josep Carreras Leukemia Research Institute and School of Medicine, University of Barcelona, Barcelona, Spain.
  6. Digestive Service, Hepatology Unit, Hospital Universitario Central de Asturias, Oviedo, Spain.
  7. Universidad de Cantabria-IDIVAL, Santander, Spain.
  8. General and Digestive Tract Surgery Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  9. Biobanco-Hospital Universitario Central de Asturias, Oviedo, Spain.
  10. Oncology Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  11. Immunology Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  12. Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain.
  13. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  14. Microbiology Service, University Hospital Marques de Valdecilla-IDIVAL, Santander, Spain.
  15. Department of Psychiatry, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.
  16. CIBERSAM, Centro de Investigación Biomédica en Red Salud Mental, Madrid, Spain.
  17. Department of Pathology, Fundación Jiménez Díaz, Madrid, Spain.

PMID: 30112114 PMCID: PMC6089396 DOI: 10.18632/oncotarget.25766

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. There is increasing interest in developing specific markers to serve as predictors of response to sorafenib and to guide targeted therapy. Using a sequencing platform designed to study somatic mutations in a selection of 112 genes (HepatoExome), we aimed to characterize lesions from HCC patients and cell lines, and to use the data to study the biological and mechanistic effects of case-specific targeted therapies used alone or in combination with sorafenib. We characterized 331 HCC cases in silico and 32 paired samples obtained prospectively from primary tumors of HCC patients. Each case was analyzed in a time compatible with the requirements of the clinic (within 15 days). In 53% of the discovery cohort cases, we detected unique mutational signatures, with up to 34% of them carrying mutated genes with the potential to guide therapy. In a panel of HCC cell lines, each characterized by a specific mutational signature, sorafenib elicited heterogeneous mechanistic and biological responses, whereas targeted therapy provoked the robust inhibition of cell proliferation and DNA synthesis along with the blockage of AKT/mTOR signaling. The combination of sorafenib with targeted therapies exhibited synergistic anti-HCC biological activity concomitantly with highly effective inhibition of MAPK and AKT/mTOR signaling. Thus, somatic mutations may lead to identify case-specific mechanisms of disease in HCC lesions arising from multiple etiologies. Moreover, targeted therapies guided by molecular characterization, used alone or in combination with sorafenib, can effectively block important HCC disease mechanisms.

Keywords: AKT/mTOR; hepatocellular carcinoma; mutations; sorafenib; targeted therapy

Conflict of interest statement

CONFLICTS OF INTEREST MV: Advisory boards, conferences, travel grants from Bayer. MAP has the following COI: Takeda-advisory board. Novartis, Amgen and Roche: Speaker bureau. CRL: Bayer HealthCare adv

References

  1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  2. Gastroenterology. 2016 Apr;150(4):835-53 - PubMed
  3. Gastroenterology. 2015 Oct;149(5):1226-1239.e4 - PubMed
  4. Lancet. 2012 Mar 31;379(9822):1245-55 - PubMed
  5. Clin Cancer Res. 2013 May 1;19(9):2310-8 - PubMed
  6. Nat Genet. 2015 May;47(5):505-511 - PubMed
  7. Oncotarget. 2015 Sep 22;6(28):25452-65 - PubMed
  8. Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11 - PubMed
  9. Int Rev Cell Mol Biol. 2008;268:1-37 - PubMed
  10. Genome Res. 2010 Sep;20(9):1297-303 - PubMed
  11. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  12. World J Gastroenterol. 2015 May 14;21(18):5445-53 - PubMed
  13. Leukemia. 2014 Jun;28(6):1334-40 - PubMed
  14. Cancer Res. 2004 Sep 1;64(17):6058-64 - PubMed
  15. Clin Cancer Res. 2017 Aug 1;23(15):4364-4375 - PubMed
  16. J Hepatol. 2003 Feb;38(2):200-7 - PubMed
  17. Clin Cancer Res. 2014 Apr 15;20(8):2072-9 - PubMed
  18. Mol Cancer Ther. 2008 Oct;7(10):3129-40 - PubMed
  19. Cancer Res. 2009 Sep 15;69(18):7385-92 - PubMed
  20. Nat Genet. 2012 May 06;44(6):694-8 - PubMed
  21. Nat Med. 2014 Oct;20(10):1138-46 - PubMed
  22. Front Pharmacol. 2016 Jun 08;7:151 - PubMed
  23. J Hepatol. 2010 Apr;52(4):550-9 - PubMed
  24. Med Clin (Barc). 2016 Jun 3;146(11):511.e1-511.e22 - PubMed
  25. J Hepatol. 2012 Jun;56(6):1330-5 - PubMed
  26. Nat Commun. 2013;4:2218 - PubMed
  27. Gastroenterology. 2012 May;142(6):1264-1273.e1 - PubMed
  28. Oncotarget. 2017 Apr 20;8(40):69076-69085 - PubMed
  29. J Hepatol. 2015 Apr;62(1 Suppl):S144-56 - PubMed
  30. Bioinformatics. 2009 Jul 15;25(14):1754-60 - PubMed
  31. N Engl J Med. 2011 Sep 22;365(12):1118-27 - PubMed

Publication Types